Themis Medicare Limited
NSEI:THEMISMED Stok Raporu
Themis Medicare Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6 Themis Medicare yıllık ortalama 16.9% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.5% annual. Gelirler growing yılda ortalama 15.4% oranında artmaktadır. Themis Medicare'in özkaynak karlılığı 12.9% ve net marjı 12.6%'dir.
Anahtar bilgiler Pharmaceuticals Sektör Büyümesi 17.5% Gelir büyüme oranı 15.4% Özkaynak getirisi 12.9% Net Marj 12.6% Sonraki Kazanç Güncellemesi 14 Feb 2025
Yakın geçmiş performans güncellemeleri
Second quarter 2025 earnings released: EPS: ₹1.55 (vs ₹1.23 in 2Q 2024) Oct 26
Themis Medicare Limited to Report Q2, 2025 Results on Oct 25, 2024 Oct 19
First quarter 2025 earnings released: EPS: ₹2.68 (vs ₹1.98 in 1Q 2024) Jul 27
Themis Medicare Limited to Report Q4, 2024 Results on Jul 26, 2024 Jul 16
Full year 2024 earnings released: EPS: ₹4.73 (vs ₹6.18 in FY 2023) Jun 28 Themis Medicare Limited to Report Q1, 2025 Results on Aug 14, 2024
Tüm güncellemeleri göster
Second quarter 2025 earnings released: EPS: ₹1.55 (vs ₹1.23 in 2Q 2024) Oct 26
Themis Medicare Limited to Report Q2, 2025 Results on Oct 25, 2024 Oct 19
New minor risk - Share price stability Sep 25
Investor sentiment improves as stock rises 16% Sep 16
Themis Medicare Limited Announces Executive Changes Aug 01
First quarter 2025 earnings released: EPS: ₹2.68 (vs ₹1.98 in 1Q 2024) Jul 27
Themis Medicare Limited Approves Dividend for the Financial Year Ended 31 March 2024 Jul 23
Themis Medicare Limited to Report Q4, 2024 Results on Jul 26, 2024 Jul 16
Upcoming dividend of ₹0.50 per share Jul 05
Full year 2024 earnings released: EPS: ₹4.73 (vs ₹6.18 in FY 2023) Jun 28 Themis Medicare Limited to Report Q1, 2025 Results on Aug 14, 2024
Themis Medicare Limited, Annual General Meeting, Jul 22, 2024 May 17
Full year 2024 earnings released: EPS: ₹4.73 (vs ₹6.18 in FY 2023) May 16
Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024 May 15
Themis Medicare Limited to Report Q4, 2024 Results on May 14, 2024 May 05
Investor sentiment improves as stock rises 19% Feb 19
Third quarter 2024 earnings released: EPS: ₹0.80 (vs ₹1.45 in 3Q 2023) Feb 11
What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You Dec 27
Investor sentiment improves as stock rises 21% Dec 26
Investor sentiment improves as stock rises 16% Dec 04
Themis Medicare (NSE:THEMISMED) Takes On Some Risk With Its Use Of Debt Dec 01
Investor sentiment improves as stock rises 16% Nov 13
New minor risk - Share price stability Nov 10
Second quarter 2024 earnings released: EPS: ₹12.30 (vs ₹1.93 in 2Q 2023) Nov 06
New minor risk - Market cap size Oct 09
Investor sentiment deteriorates as stock falls 90% Oct 09
High number of new directors Oct 01
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 Sep 08
Upcoming dividend of ₹5.00 per share at 0.3% yield Aug 25 Themis Medicare Limited to Report First Half, 2024 Results on Nov 14, 2023
Themis Medicare (NSE:THEMISMED) Has Affirmed Its Dividend Of ₹5.00 Aug 18
First quarter 2024 earnings released: EPS: ₹19.77 (vs ₹18.92 in 1Q 2023) Aug 11
Themis Medicare Limited to Report Q1, 2024 Results on Aug 10, 2023 Aug 04
Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00 Aug 04
Themis Medicare Limited to Report Q1, 2024 Results on Aug 12, 2023 Aug 03
Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00 Jul 18
We Think Themis Medicare (NSE:THEMISMED) Is Taking Some Risk With Its Debt Jul 08
Themis Medicare (NSE:THEMISMED) Is Due To Pay A Dividend Of ₹5.00 May 18
Full year 2023 earnings released: EPS: ₹61.81 (vs ₹79.22 in FY 2022) May 15 Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023
Themis Medicare Limited to Report Q4, 2023 Results on May 13, 2023 May 05
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing Feb 17
Third quarter 2023 earnings released: EPS: ₹14.47 (vs ₹13.54 in 3Q 2022) Feb 05
Themis Medicare Limited to Report Q3, 2023 Results on Feb 03, 2023 Jan 28
Insider recently sold ₹1.1m worth of stock Jan 06
Themis Medicare Ltd. Launches Lenzetto Global Brand of Estradiol Novel Drug Delivery System Jan 05
Themis Medicare Ltd. Launches Lenzetto Global Brand of Estradiol Novel Drug Delivery System Jan 04
Themis Medicare (NSE:THEMISMED) Seems To Use Debt Quite Sensibly Dec 21
Investor sentiment improved over the past week Dec 14
Less than half of directors are independent Nov 16
Second quarter 2023 earnings released: EPS: ₹19.33 (vs ₹20.95 in 2Q 2022) Nov 08
Themis Medicare Limited to Report Q2, 2023 Results on Nov 07, 2022 Nov 01
Less than half of directors are independent Sep 30 Themis Medicare Limited Informs the Second Term of Office of Mr. Hoshang Sinor as Independent Director, Come to End
Investor sentiment improved over the past week Sep 09
Themis Medicare Limited Announces Resignation of Lajos Kovacs as Board of Directors Sep 08
Upcoming dividend of ₹5.00 per share Sep 01
Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00 Aug 28
Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00 Aug 08
First quarter 2023 earnings released: EPS: ₹37.84 (vs ₹33.93 in 1Q 2022) Jul 30
Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's Jul 21
Themis Medicare Limited to Report Q1, 2023 Results on Jul 28, 2022 Jul 20
Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's May 27
Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2022 May 22
Full year 2022 earnings released: EPS: ₹79.22 (vs ₹38.86 in FY 2021) May 22
Themis Medicare Limited, Annual General Meeting, Sep 19, 2022 May 22
Themis Medicare Limited Announces Approval for Drug VIRALEX by the Drug Controller General of India May 19
Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist? May 12
Now 21% undervalued after recent price drop May 11
Themis Medicare Limited Announces Resignation of Jayshree Dinesh Patel as Whole-Time Director Mar 29
Themis Medicare Limited Announces Approval of Its Antiviral Drug VIRALEX by the Drug Controller General of India Mar 06
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 14
Themis Medicare Limited Announces Retirement of Jayshree D Patel, Whole Time Director Feb 12
Second quarter 2022 earnings released: EPS ₹20.95 (vs ₹8.85 in 2Q 2021) Nov 15
Calculating The Fair Value Of Themis Medicare Limited (NSE:THEMISMED) Nov 09
Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist? Oct 26
Independent & Non-Executive Director Humayun Dhanrajgir has left the company Sep 23
Increases to Themis Medicare Limited's (NSE:THEMISMED) CEO Compensation Might Cool off for now Sep 11
Upcoming dividend of ₹4.30 per share Sep 01
First quarter 2022 earnings released: EPS ₹33.93 (vs ₹8.44 in 1Q 2021) Aug 18
Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹4.30 Aug 16
Investor sentiment improved over the past week Aug 13
Investor sentiment improved over the past week Jul 15
Do Themis Medicare's (NSE:THEMISMED) Earnings Warrant Your Attention? Jul 09
Insider recently sold ₹71k worth of stock Jun 25
Insider recently sold ₹695k worth of stock Jun 08
Full year 2021 earnings released: EPS ₹38.86 (vs ₹26.97 in FY 2020) May 30
Themis Medicare Limited Recommends Dividend for the Financial Year Ended March 31, 2021 May 28
Investor sentiment improved over the past week May 27
Estimating The Intrinsic Value Of Themis Medicare Limited (NSE:THEMISMED) May 14
Investor sentiment improved over the past week May 09
Investor sentiment improved over the past week Apr 24
If You Like EPS Growth Then Check Out Themis Medicare (NSE:THEMISMED) Before It's Too Late Mar 23
Themis Medicare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi NSEI:THEMISMED Gelir, gider ve kazançlar (INR Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Sep 24 4,203 530 1,057 0 30 Jun 24 4,081 500 1,012 0 31 Mar 24 3,818 435 998 0 31 Dec 23 3,640 453 896 0 30 Sep 23 3,703 512 863 0 30 Jun 23 3,565 577 700 0 31 Mar 23 3,543 569 781 0 31 Dec 22 3,540 584 711 0 30 Sep 22 3,602 576 677 0 30 Jun 22 3,765 591 575 0 31 Mar 22 3,946 729 610 0 31 Dec 21 3,766 710 529 0 30 Sep 21 3,472 703 498 0 30 Jun 21 2,947 591 407 0 31 Mar 21 2,307 357 444 0 31 Dec 20 2,151 349 456 0 30 Sep 20 2,033 338 467 0 30 Jun 20 1,987 274 436 0 31 Mar 20 2,016 248 491 0 31 Dec 19 1,911 61 521 0 30 Sep 19 1,855 -45 522 0 30 Jun 19 1,846 -64 527 0 31 Mar 19 1,838 -107 541 0 31 Dec 18 2,002 54 564 0 30 Sep 18 2,022 78 569 0 30 Jun 18 2,063 101 560 0 31 Mar 18 2,095 113 546 0 31 Dec 17 2,354 105 545 0 30 Sep 17 2,399 143 525 0 30 Jun 17 2,323 142 504 0 31 Mar 17 2,167 160 487 0 31 Dec 16 2,438 211 468 0 30 Sep 16 2,368 212 456 0 30 Jun 16 2,404 208 386 0 31 Mar 16 2,324 163 417 0 31 Dec 15 2,287 155 603 0 30 Sep 15 2,227 142 593 0 30 Jun 15 2,022 71 334 0 31 Mar 15 2,019 62 361 0 31 Mar 14 1,951 27 526 0
Kaliteli Kazançlar: THEMISMED yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: THEMISMED 'nin mevcut net kar marjları (12.6%) geçen yılın (13.8%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: THEMISMED son 5 yılda karlı hale geldi ve kazançlarını yıllık 16.9% oranında artırdı.
Büyüme Hızlandırma: THEMISMED 'un son bir yıldaki kazanç büyümesi ( 3.4% ) 5 yıllık ortalamasının ( 16.9% /yıl) altındadır.
Kazançlar vs. Sektör: THEMISMED geçen yılki kazanç büyümesi ( 3.4% ) Pharmaceuticals sektörünün 18.7% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: THEMISMED 'nin Özsermaye Getirisi ( 12.9% ) düşük olarak değerlendiriliyor.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
